Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Molecular Diagnostics: guided by the light

914 views

Published on

Molecular Diagnostics: guided by the light
24-05-2012 NYtor (Jacqueline Vet)

Published in: Health & Medicine, Technology
  • Be the first to comment

  • Be the first to like this

Molecular Diagnostics: guided by the light

  1. 1. Jacqueline Vet 24 mei 2012
  2. 2. 2007 ZZP-organisation Activities: • design and development of prototype molecular diagnostic assays • workshops/ courses Business model: contract research
  3. 3. ORGANISATION ZZP NYtor Universitair Bedrijvencentrum Toernooiveld 102 Nijmegen Molecular Beacon Lab (USA) Bio-Rad HAN BioCentre PHRI, UMDNJ, Dept. of Molecular Genetics 1. Apparatus 2. Reagents 1. Assay design 3. Network1. Collaboration agreement 2. New technological developments2. Use labspace Biolegio 3. Collaboration projects 1. primers-probe3. NYtor hires research analist synthesis4. Use both networks for new customers www.hanbiocentre.nl www.molecular-beacons.org
  4. 4. 2012 BV SERVICES DEVELOPMENTBusiness model: designed assays are licensed to suitable party : fee +royaltiesActivities: own product development
  5. 5. ORGANISATION BV NYtor office NYtor laboratory Universitair Bedrijvencentrum Mercator III Toernooiveld 102 Toernooiveld 1 Nijmegen NijmegenMolecular Beacon Lab (USA) Bio-RadPHRI, UMDNJ, Dept. of Molecular Genetics 1. Apparatus 2. Reagents1. Assay design 3. Network2. New technological developments Biolegio3. Collaboration projects 1. primers-probe synthesis www.molecular-beacons.org
  6. 6. NYtor TECHNOLOGY
  7. 7. NYtor TECHNOLOGY Molecular beacon qPCR-technology = DNA-amplification + high specific DNA-detection (target) (molecular beacon) 24-05-2012
  8. 8. NYtor TECHNOLOGY - II Multiplex Four Target PCR Assay 24-05-2012
  9. 9. NYtor TECHNOLOGY - III Technique developed at Public Health Research Institute (NY, VS) 1995-1998, postdoctoral fellowship: co-inventor / co-patent holderLicensees: > 50 e.g.: bioMerieux, Becton Dickinson, Gen-Probe, Abbott Laboratories, Bio-Rad, Affymetrix, Stratagene, Cepheid 24-05-2012
  10. 10. ApplicationsFields of use for the molecular beacons technology1. Human in vitro diagnosticsa. Testing for infectious agents 7. Agricultural infectious agentsb. Genetic testing 8. Forensicsc. Oncology 9. Paternity testing2. Research 10. High-density probe arrays3. GMO testing 11. Industrial microbiology4. Food testing 12. Blood products quality control5. Veterinary diagnostics 13. Environmental pathogens6. Hybrid seed production
  11. 11. Overview developed qPCR assays - IFOOD/WATER: •Legionella pneumophila •Legionella species •Campylobacter jejuni-coli-lari multiplex •E.coli 0157 •Listeria monocytogenes •Listeria speciesPHARMACEUTICAL: •CHO qPCR: quantitation of host-cell residual DNA from Chinese Hamster Ovary (CHO) cellsVETERINARY: •Scrapie genotyping: multiplex detection 5 SNPs (sheep) •Helicobacter ganmani-rodentium multiplex (fish) 24-05-2012
  12. 12. Overview developed qPCR assays - IICLINICAL: •HIV-1, HIV-2, HTLV-II and HTLV-II multiplex •Chlamydia pneumonia and Mycoplasma pneumonia multiplex •Clostridium difficile ribotypes 017 and 027 multiplex •Methylenetetrahydrofolate reductase (MTHFR)-gene (cardiovascular disease)MISCELLANEOUS •RT-qPCR assay to dermine optimum moment of harvesting (pears) •Lactococcus lactis spp. lactis, spp. cremoris, spp. lactis biovar diacetylactis and ,Leuconostoc monoplex (starter cultures yogurt and cheese) 24-05-2012
  13. 13. PROJECTS BV 1. Superbug project (EFRO) - Check-Points 2. Veterinary diagnostics - Biochek 3. Personalized Medicine - Future Diagnostics 24-05-2012
  14. 14. SUPERBUG PROJECT- Fast increase multi resistant bacteria (superbugs)- Cause resistance: enzymes destroy antibiotics • Extended Spectrum Beta-Lactamases (ESBL) • Klebsiella Pneumonia Carbapenemase (KPC) • New Delhi Metallo-Beta-Lactamase (NDM-1) - ESBLs in Klebsiella pneumoniae 2002 2005 2008 Bron: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx Crucial: identification of bacteria at early stage • optimal treatment of patient • timely detection outbreaks  prevent spread 24-05-2012
  15. 15. PRODUCT DEVELOPMENT SuperBug assay Rapid test for detection of multi resistant bacteria DNA PROBE-LIGATIE MICROARRAYconventionele EXTRACTIE INCUBATIE INCUBATIE & ANALYSE test 1 uur 3,5 uur 2,5 uur SuperBug DNA qPCR EXTRACTIE met MB assay 1 uur 1 uur 0 2 7 Tijd (uren)  Essential time saving ! (5 hour reduction to detection) 24-05-2012
  16. 16. SAMENWERKINGSPARTNERBedrijfsstrategie NYtor: ontwikkelde testen worden ter licentie aangebodenaan een geschikte marktpartij met bijbehorende royaltyregeling.Voor de SuperBug assay samenwerking met:Check-Points BV (Wageningen)• wereldwijde marktleider op gebied van analyse van gramnegatieve bacteriën.• internationaal distributienetwerk in 30 landenNYtor + Check-Points: sterk team  snelle en efficiënte onwikkeling vande superbug assay 24-05-2011
  17. 17. SUPERBUG – INVESTMENT/EARNINGS % EFRO grant 50 Upfront Fee 25 NYtor/KERN 25 Total 100 700 600 SuperBug assay – 10 year prognosis 500 400 REALISTIC 300 200 WORST CASE 100 OPTIMISTIC 0-100 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020-200 24-05-2011
  18. 18. ‘PERSONALIZED MEDICINE’-ASSAYS• accurate diagnostic tests that identify patients who can benefit from targeted therapies• Strategic collaboration with Future Diagnostics NYtor: prototype assay development Future diagnostics: validation of the prototype assays
  19. 19. FUTURE PERSPECTIVES• Lab-on-a-Chip: coupling self-reporting molecular beacons to micro array format• Sloppy molecular beacons: increase multiplex format of qPCR up to hunderd targets
  20. 20. FUTURE CHALLENGES • new facilities • NYtor team: find right people • financing • business strategy

×